Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children

被引:20
作者
Boonacker, Chantal W. B. [1 ]
Broos, Pieter H. [1 ]
Sanders, Elisabeth A. M. [2 ]
Schilder, Anne G. M. [1 ,3 ]
Rovers, Maroeska M. [1 ,3 ]
机构
[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Clin Dept Clin Immunol & Infect Dis, Wilhelmina Childrens Hosp, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Otorhinolaryngol, Wilhelmina Childrens Hosp, NL-3508 GA Utrecht, Netherlands
关键词
NONTYPABLE HAEMOPHILUS-INFLUENZAE; PHARMACOECONOMIC EVALUATION; ECONOMIC-EVALUATION; EPIDEMIOLOGY; IMPACT; IMMUNIZATION; PREVENTION; EFFICACY; INFANTS; PROGRAM;
D O I
10.2165/11584930-000000000-00000
中图分类号
F [经济];
学科分类号
02 ;
摘要
While pneumococcal conjugate vaccines have shown to be highly effective against invasive pneumococcal disease, their potential effectiveness against acute otitis media (AOM) might become a major economic driver for implementing these vaccines in national immunization programmes. However, the relationship between the costs and benefits of available vaccines remains a controversial topic. Our objective is to systematically review the literature on the cost effectiveness of pneumococcal conjugate vaccination against AOM in children. We searched PubMed, Cochrane and the Centre for Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects [DARE], NHS Economic Evaluation Database [NHS EED] and Health Technology Assessment database [HTA]) from inception until 18 February 2010. We used the following keywords with their synonyms: 'otitis media', 'children', 'cost-effectiveness', 'costs' and 'vaccine'. Costs per AOM episode averted were calculated based on the information in this literature. A total of 21 studies evaluating the cost effectiveness of pneumococcal conjugate vaccines were included. The quality of the included studies was moderate to good. The cost per AOM episode averted varied from (sic)168 to (sic)4214, and assumed incidence rates varied from 20 952 to 118 000 per 100 000 children aged 0-10 years. Assumptions regarding direct and indirect costs varied between studies. The assumed vaccine efficacy of the 7-valent pneumococcal CRM197-conjugate vaccine was mainly adopted from two trials, which reported 6-8% efficacy. However, some studies assumed additional effects such as herd immunity or only took into account AOM episodes caused by serotypes included in the vaccine, which resulted in efficacy rates varying from 12% to 57%. Costs per AOM episode averted were inversely related to the assumed incidence rates of AOM and to the estimated costs per AOM episode. The median costs per AOM episode averted tended to be lower in industry-sponsored studies. Key assumptions regarding the incidence and costs of AOM episodes have major implications for the estimated cost effectiveness of pneumococcal conjugate vaccination against AOM. Uniform methods for estimating direct and indirect costs of AOM should be agreed upon to reliably compare the cost effectiveness of available and future pneumococcal vaccines against AOM.
引用
收藏
页码:199 / 211
页数:13
相关论文
共 50 条
  • [1] A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain
    Asensi, F
    De Jose, M
    Lorente, M
    Moraga, F
    Ciuryla, V
    Arikian, S
    Casciano, R
    Vento, M
    [J]. VALUE IN HEALTH, 2004, 7 (01) : 36 - 51
  • [2] Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden
    Bergman, Annika
    Hjelmgren, Jonas
    Ortqvist, Ake
    Wilsloff, Torbjorn
    Kristiansen, Ivar Sonbo
    Hogberg, Liselotte Diaz
    Persson, Kristina M-S
    Persson, Ulf
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 40 (09) : 721 - 729
  • [3] Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000)
    Beutels, P
    [J]. HEALTH ECONOMICS, 2001, 10 (08) : 751 - 774
  • [4] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [5] Direct expenditures related to otitis media diagnoses: Extrapolations from a pediatric medicaid cohort
    Bondy, J
    Berman, S
    Glazner, J
    Lezotte, D
    [J]. PEDIATRICS, 2000, 105 (06) : art. no. - e72
  • [6] Combination vaccine against invasive meningococcal B and pneumococcal infections -: Potential epidemiological and economic impact in The Netherlands
    Bos, JM
    Rümke, HC
    Welte, R
    Spanjaard, L
    van Alphen, L
    Postma, MJ
    [J]. PHARMACOECONOMICS, 2006, 24 (02) : 141 - 153
  • [7] Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands
    Bos, JM
    Rümke, H
    Welte, R
    Postma, MJ
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (10) : 2614 - 2630
  • [8] Health-related quality of life in children with otitis media
    Brouwer, CNM
    Maillé, AR
    Rovers, MM
    Grobbee, DE
    Sanders, EAM
    Schilder, AGM
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2005, 69 (08) : 1031 - 1041
  • [9] The cost-effectiveness of pneumococcal conjugate vaccination in Australia
    Butler, JRG
    McIntyre, P
    MacIntyre, CR
    Gilmour, R
    Howarth, AL
    Sander, B
    [J]. VACCINE, 2004, 22 (9-10) : 1138 - 1149
  • [10] Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
    Campbell, Helen
    Andrews, Nick
    Borrow, Ray
    Trotter, Caroline
    Miller, Elizabeth
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (05) : 840 - 847